Adar1 Capital Management, LLC Portfolio Holdings

Adar1 Capital Management, LLC

  • $500 Billion
  • Q4 2024

Adar1 Capital Management, LLC has filed its 13F form on February 13, 2025 for Q4 2024 where it was disclosed a total value porftolio of $500 Billion distributed in 214 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Roivant Sciences Ltd. with a value of $41.5B, Protagonist Therapeutics, Inc with a value of $39.4B, Ea Series Trust with a value of $35.9B, Zai Lab LTD with a value of $27.4B, and Immunovant, Inc. with a value of $19.5B.

Examining the 13F form we can see an decrease of $115B in the current position value, from $615B to 500B.

Adar1 Capital Management, LLC is based out at Austin, TX

Below you can find more details about Adar1 Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $500 Billion
Healthcare: $303 Billion
ETFs: $17.1 Billion
Communication Services: $6.59 Billion
Utilities: $178 Million
Energy: $111 Million
Financial Services: $588,000

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$7.36B
$41.5 Billion 8.3% of portfolio
3,508,694
Q4 2024 Added 15.97%
$1.9B
$39.4 Billion 7.87% of portfolio
1,020,333
Q4 2024 Added 3.98%
Ea Series Trust
-
$35.9 Billion 7.17% of portfolio
-
Q4 2024 Added 0.64%
$2.82B
$27.4 Billion 5.47% of portfolio
1,045,837
Q4 2024 Added 96.42%
$3.55B
$19.5 Billion 3.9% of portfolio
787,478
Q4 2024 Reduced 30.42%
$3.92B
$19.5 Billion 3.89% of portfolio
414,209
Q4 2024 Reduced 54.54%
$4.68B
$18.6 Billion 3.72% of portfolio
678,857
Q4 2024 Reduced 53.13%
Inhibikase Therapeutics Inc
-
$16.6 Billion 3.31% of portfolio
-
Q4 2024 New
$0
$12 Billion 2.41% of portfolio
131,786
Q4 2024 Added 504.91%
Abivax Sa
-
$11.1 Billion 2.21% of portfolio
-
Q4 2024 Added 190.14%
Mineralys Therapeutics Inc
-
$10.4 Billion 2.07% of portfolio
-
Q4 2024 Added 15.37%
$7.95B
$9.83 Billion 1.96% of portfolio
71,402
Q4 2024 Reduced 55.76%
Perceptive Cap Solutions Cor
-
$7.64 Billion 1.53% of portfolio
-
Q2 2024 New
$3.62B
$7.44 Billion 1.49% of portfolio
170,000
Q4 2024 Added 283.31%
$191M
$6.66 Billion 1.33% of portfolio
1,359,208
Q4 2024 Reduced 13.52%
$10.2B
$6.59 Billion 1.32% of portfolio
210,729
Q4 2024 Added 71.59%
Anteris Technologies Global
-
$5.88 Billion 1.17% of portfolio
-
Q4 2024 New
Aa Mission Acquisition Corp
-
$5.66 Billion 1.13% of portfolio
-
Q4 2024 Reduced 44.55%
Coherus Biosciences Inc
-
$5.48 Billion 1.09% of portfolio
-
Q4 2024 New
$972M
$5.39 Billion 1.08% of portfolio
234,607
Q4 2024 Reduced 31.45%
Zura Bio LTD
-
$5.19 Billion 1.04% of portfolio
-
Q4 2024 Reduced 44.91%
$495M
$5.08 Billion 1.02% of portfolio
1,554,802
Q4 2024 Reduced 25.58%
Oaktree Acquisition Corp Iii
-
$5.07 Billion 1.01% of portfolio
-
Q4 2024 New
$9.59B
$4.86 Billion 0.97% of portfolio
40,002
Q4 2024 Added 463.41%
$135B
$4.8 Billion 0.96% of portfolio
99,600
Q4 2024 New
Gossamer Bio Inc
-
$4.36 Billion 0.87% of portfolio
-
Q4 2024 New
Helix Acquisition Corp Ii
-
$4.24 Billion 0.85% of portfolio
-
Q2 2024 Added 0.16%
$511M
$4.03 Billion 0.81% of portfolio
515,138
Q4 2024 Added 7,752.71%
Bridgebio Pharma Inc
-
$3.86 Billion 0.77% of portfolio
-
Q4 2024 New
$1.85B
$3.43 Billion 0.68% of portfolio
81,460
Q4 2024 Reduced 46.86%
Kiniksa Pharmaceuticals Intl
-
$3.29 Billion 0.66% of portfolio
-
Q4 2024 Reduced 61.89%
$18.5B
$3.23 Billion 0.65% of portfolio
146,671
Q4 2024 Added 35.59%
$377M
$3.23 Billion 0.65% of portfolio
647,960
Q4 2024 Added 114.41%
$323M
$3.03 Billion 0.61% of portfolio
988,468
Q4 2024 Added 33.1%
Grace Therapeutics Inc
-
$2.89 Billion 0.58% of portfolio
-
Q4 2024 Reduced 19.38%
Monopar Therapeutics Inc
-
$2.86 Billion 0.57% of portfolio
-
Q4 2024 New
$1.9B
$2.72 Billion 0.54% of portfolio
53,125
Q4 2024 Reduced 39.92%
Tectonic Therapeutic Inc
-
$2.71 Billion 0.54% of portfolio
-
Q4 2024 Reduced 53.83%
$766M
$2.66 Billion 0.53% of portfolio
211,400
Q4 2024 Added 4,816.28%
$1.66B
$2.58 Billion 0.52% of portfolio
154,027
Q4 2024 Added 561.0%
$60.1M
$2.46 Billion 0.49% of portfolio
928,016
Q4 2024 Added 720.71%
Korro Bio Inc
-
$2.21 Billion 0.44% of portfolio
-
Q4 2024 Added 17.24%
A Spac Iii Acquisition Corp
-
$2.17 Billion 0.43% of portfolio
-
Q4 2024 New
$3.55B
$2.17 Billion 0.43% of portfolio
48,023
Q4 2024 Added 140.11%
Bridgebio Pharma Inc
-
$2.1 Billion 0.42% of portfolio
-
Q4 2024 New
$2.44B
$1.98 Billion 0.4% of portfolio
50,547
Q4 2024 Added 81.15%
Apogee Therapeutics Inc
-
$1.87 Billion 0.37% of portfolio
-
Q4 2024 Reduced 27.82%
$35.3M
$1.86 Billion 0.37% of portfolio
1,174,313
Q4 2024 Added 15,557.51%
$137M
$1.8 Billion 0.36% of portfolio
149,385
Q4 2024 Added 381.08%

Summary

  • Portfolio
  • No. of Stocks 214
  • Current Value $500 Billion
  • Prior Value $615 Billion
  • Filing
  • Period Q4 2024
  • Filing Date February 13, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 46 stocks
  • Additional Purchases 54 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 66 stocks
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email